MBX Biosciences, Inc. (MBX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$48.50-3.88%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge MBX Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.942
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-3.071
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-3.984

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance canvuparatide to Phase 3 trial by Q3 2026	MBX plans to start a Phase 3 trial for canvuparatide in Q3 2026.	Intact	Phase 3 trial not started by Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Add two new obesity drug candidates in 2026	The company aims to add two new obesity drug candidates in 2026.	Improving	Fewer than two new obesity candidates added in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management highlighted advancing MBX 4291 Phase 1 trial with promising once-monthly dosing potential and nominated two novel candidates, MBX 5765 and MBX 6180, expanding the obesity portfolio. Progress is on track with data readouts and candidate nominations expected. Delivery assessment Oct 24, 2026
Lease new office and laboratory space in Burlington, MA	It also leased new lab space to support growth.	Intact	No new lab space leased by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.98

$-3.93 → $-3.98 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.93	$0	9 / 8
2026-07-25	$-3.60	$0	8 / 8
2026-07-26	$-3.60	$0	8 / 8
2026-07-27	$-3.88	Unavailable	8 / 0
2026-07-28	$-3.60	$0	8 / 8
2026-07-29	$-3.60	$0	8 / 8
2026-07-30	$-3.60	$0	8 / 8
2026-07-31	$-3.62	$0	8 / 8
2026-08-01	$-3.65	Unavailable	7 / 0
2026-08-02	$-3.62	$0	8 / 8
2026-08-03	$-3.62	$0	8 / 8
2026-08-04	$-3.62	$0	8 / 8
2026-08-05	$-3.62	$0	8 / 8
2026-08-06	$-3.65	Unavailable	7 / 0
2026-08-07	$-3.65	Unavailable	7 / 0
2026-08-08	$-3.76	$0	8 / 7
2026-08-09	$-3.76	$0	8 / 7
2026-08-10	$-3.76	$0	8 / 7
2026-08-12	$-3.65	Unavailable	7 / 0
2026-08-13	$-3.65	Unavailable	7 / 0
2026-08-14	$-3.65	Unavailable	7 / 0
2026-08-15	$-3.65	Unavailable	7 / 0
2026-08-16	$-3.65	Unavailable	7 / 0
2026-08-17	$-3.65	Unavailable	7 / 0
2026-08-18	$-3.65	Unavailable	7 / 0
2026-08-19	$-3.65	Unavailable	7 / 0
2026-08-20	$-4.00	Unavailable	7 / 0
2026-08-21	$-4.00	Unavailable	7 / 0
2026-08-22	$-4.00	Unavailable	7 / 0
2026-08-23	$-4.00	Unavailable	8 / 0
2026-08-24	$-4.00	Unavailable	8 / 0
2026-08-25	$-4.00	Unavailable	8 / 0
2026-08-26	$-4.00	Unavailable	8 / 0
2026-08-27	$-4.00	Unavailable	8 / 0
2026-08-28	$-4.00	Unavailable	8 / 0
2026-08-29	$-4.00	Unavailable	8 / 0
2026-08-30	$-4.00	Unavailable	8 / 0
2026-08-31	$-4.00	Unavailable	8 / 0
2026-09-01	$-4.00	Unavailable	8 / 0
2026-09-02	$-4.00	Unavailable	8 / 0
2026-09-03	$-4.00	Unavailable	8 / 0
2026-09-04	$-4.00	Unavailable	8 / 0
2026-09-05	$-4.00	Unavailable	8 / 0
2026-09-06	$-4.00	Unavailable	8 / 0
2026-09-07	$-4.00	Unavailable	8 / 0
2026-09-08	$-4.00	Unavailable	8 / 0
2026-09-09	$-4.00	Unavailable	8 / 0
2026-09-10	$-4.00	Unavailable	8 / 0
2026-09-11	$-4.00	Unavailable	8 / 0
2026-09-12	$-4.00	Unavailable	8 / 0
2026-09-13	$-4.00	Unavailable	8 / 0
2026-09-14	$-4.00	Unavailable	8 / 0
2026-09-15	$-4.00	Unavailable	8 / 0
2026-09-16	$-4.00	Unavailable	8 / 0
2026-09-17	$-4.03	Unavailable	8 / 0
2026-09-18	$-4.03	Unavailable	8 / 0
2026-09-19	$-4.03	Unavailable	8 / 0
2026-09-20	$-4.03	Unavailable	8 / 0
2026-09-21	$-4.03	Unavailable	8 / 0
2026-09-22	$-4.00	Unavailable	8 / 0
2026-09-23	$-4.00	Unavailable	8 / 0
2026-09-24	$-4.00	Unavailable	8 / 0
2026-09-25	$-4.00	Unavailable	8 / 0
2026-09-26	$-4.00	Unavailable	8 / 0
2026-09-27	$-4.00	Unavailable	8 / 0
2026-09-28	$-4.00	Unavailable	8 / 0
2026-09-29	$-4.00	Unavailable	8 / 0
2026-09-30	$-4.00	Unavailable	8 / 0
2026-10-01	$-4.00	Unavailable	7 / 0
2026-10-02	$-4.00	Unavailable	7 / 0
2026-10-03	$-4.02	Unavailable	7 / 0
2026-10-04	$-4.02	Unavailable	7 / 0
2026-10-05	$-4.02	Unavailable	7 / 0
2026-10-06	$-4.02	Unavailable	7 / 0
2026-10-07	$-4.02	Unavailable	7 / 0
2026-10-08	$-4.02	Unavailable	7 / 0
2026-10-09	$-4.02	Unavailable	7 / 0
2026-10-10	$-4.02	Unavailable	7 / 0
2026-10-11	$-4.02	Unavailable	7 / 0
2026-10-12	$-3.98	Unavailable	7 / 0
2026-10-13	$-3.98	Unavailable	7 / 0
2026-10-14	$-3.98	Unavailable	7 / 0
2026-10-15	$-3.98	Unavailable	7 / 0
2026-10-16	$-3.98	Unavailable	7 / 0
2026-10-17	$-3.98	Unavailable	7 / 0
2026-10-18	$-3.98	Unavailable	7 / 0
2026-10-19	$-3.98	Unavailable	7 / 0
2026-10-20	$-3.98	Unavailable	7 / 0
2026-10-21	$-3.98	Unavailable	7 / 0
2026-10-22	$-3.98	Unavailable	7 / 0
2026-10-23	$-3.98	Unavailable	7 / 0
2026-10-24	$-3.98	Unavailable	7 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	11	1
2026-06-01	11	1
2026-07-01	11	1
2026-08-01	12	0
2026-09-01	12	0
2026-10-01	11	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausOct 12 · prior May 12

$56.00 → $84.00+50.0%

GuggenheimOct 2

$150.00New observation · no comparable prior

$0$82.50$165.00

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance canvuparatide to Phase 3 trial by Q3 2026Direct metric needs a verified mapping
Add two new obesity drug candidates in 2026Direct metric needs a verified mapping
Lease new office and laboratory space in Burlington, MADirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-37.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

MBX Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

MBX is a speculative, clinical-stage growth story, meaning its long-term case depends on developing drug candidates rather than established earnings. The thesis is on watch: canvuparatide’s Phase 3 trial is underway, but recent financial performance is weak and management execution has been volatile.

What's priced into MBX Biosciences, Inc.

The evidence does not provide a usable valuation comparison or a clear account of what the market already assumes, so the expectations gap is uncertain. The priced-in assessment reports low fragility, but that does not resolve the valuation picture.

What the fundamentals likely do

Near term, losses and weak recent performance leave MBX exposed to a possible miss; the evidence flags a 45% miss probability, and a recent earnings miss adds concern. Over the multi-year view, Phase 3 enrollment is underway, the obesity portfolio is expanding with mixed progress, and cash supports management’s stated runway into 2029.

What MBX Biosciences, Inc. hinges on

The thesis hinges on canvuparatide advancing through Phase 3 and the newer obesity candidates producing meaningful progress. A guidance cut or further weakening in employment data could weigh on the business setting, while stronger results from healthcare peers could support sector momentum.